Crossmark

Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism

Crossref DOI link: https://doi.org/10.1038/s41467-023-36630-w

Published Online: 2023-03-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Upadhyayula, Pavan S. http://orcid.org/0000-0003-2071-6965
Higgins, Dominique M.

Mela, Angeliki http://orcid.org/0000-0003-0099-9267
Banu, Matei

Dovas, Athanassios

Zandkarimi, Fereshteh

Patel, Purvi

Mahajan, Aayushi

Humala, Nelson

Nguyen, Trang T. T. http://orcid.org/0000-0001-8747-9082
Chaudhary, Kunal R.

Liao, Lillian

Argenziano, Michael

Sudhakar, Tejaswi

Sperring, Colin P.

Shapiro, Benjamin L. http://orcid.org/0000-0002-9300-7695
Ahmed, Eman R.

Kinslow, Connor

Ye, Ling F.

Siegelin, Markus D. http://orcid.org/0000-0001-7113-3634
Cheng, Simon

Soni, Rajesh

Bruce, Jeffrey N. http://orcid.org/0000-0002-6844-0286
Stockwell, Brent R. http://orcid.org/0000-0002-3532-3868
Canoll, Peter http://orcid.org/0000-0002-7001-0226
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS103473, R61NS109407, R01NS103473)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA87497, R35CA209896)

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke

Emerson Health Collective Cancer Research Fund

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke

Emerson Collective Cancer Research Fund
License Information

Text and Data Mining valid from 2023-03-02

Version of Record valid from 2023-03-02
More Information

Article History

Received: 21 June 2021

Accepted: 7 February 2023

First Online: 2 March 2023

Competing interests

: B.R.S., D.M.H., P.C., J.N.B., A.D., K.R.C., S.C., P.S.U. are inventors on patents and patent applications involving ferroptosis. B.R.S. co-founded and serves as a consultant to Inzen Therapeutics, Exarta Therapeutics, and ProJenX, Inc., serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP, and receives sponsored research support from Sumitomo Dainippon Pharma Oncology.

Document is current

Any future updates will be listed below